Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-017175
Filing Date
2023-05-03
Accepted
2023-05-03 16:10:07
Documents
63
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20230331.htm   iXBRL 10-Q 2791442
2 EX-31.1 fate-ex31_1.htm EX-31 15520
3 EX-31.2 fate-ex31_2.htm EX-31 15615
4 EX-32.1 fate-ex32_1.htm EX-32 10991
  Complete submission text file 0000950170-23-017175.txt   11840725

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fate-20230331_cal.xml EX-101.CAL 45558
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20230331.xsd EX-101.SCH 67642
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20230331_pre.xml EX-101.PRE 415912
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20230331_lab.xml EX-101.LAB 538028
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fate-20230331_def.xml EX-101.DEF 286299
57 EXTRACTED XBRL INSTANCE DOCUMENT fate-20230331_htm.xml XML 2867895
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 23883790
SIC: 2836 Biological Products, (No Diagnostic Substances)